Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Moodys
Teva
AstraZeneca
Argus Health
Queensland Health

Generated: April 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,259,186

« Back to Dashboard

Which drugs does patent 7,259,186 protect, and when does it expire?

Patent 7,259,186 protects TRILIPIX and is included in one NDA.

This patent has nineteen patent family members in eleven countries.

Summary for Patent: 7,259,186
Title:Salts of fenofibric acid and pharmaceutical formulations thereof
Abstract:In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients.In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
Inventor(s): Cink; Russell Drew (Grayslake, IL), Paterson, Jr.; Joseph B. (Vernon Hills, IL), Gao; Yi (Vernon Hills, IL), Zhang; Geoff G. Z. (Libertyville, IL), Long; Michelle A. (Libertyville, IL), Morris; John B. (Grayslake, IL), Rosenberg; Joerg (Ellerstadt, DE)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/880,851
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,259,186
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,259,186
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation;

Drugs Protected by US Patent 7,259,186

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-001 Dec 15, 2008 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-002 Dec 15, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,259,186

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 359777 ➤ Sign Up
Australia 2003290060 ➤ Sign Up
Australia 2010249244 ➤ Sign Up
Canada 2510261 ➤ Sign Up
China 100473378 ➤ Sign Up
China 101480384 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Moodys
UBS
Chubb
US Army
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.